DNJ
1-Deoxynojirimycin (DNJ) is a glucose analog that acts as a glycosidase inhibitor and is found in significant quantities in mulberry leaves. It has been researched for its potential antidiabetic, antiviral, and antiobesity effects. DNJ inhibits glycosidase enzymes, which are involved in the digestion and absorption of carbohydrates in the intestines.
- Category
- Bioactive Compound
- Molecular Formula
- C6H13NO4
- Mechanism of Action
- DNJ works by inhibiting enzymes called glycosidases in the intestines, which are responsible for the digestion of complex carbohydrates into glucose. This inhibition can slow the absorption of glucose into the bloodstream, thereby potentially lowering blood sugar levels.
- Evidence Grade
- C - Unclear or conflicting scientific evidence
Other Names
- 1-Deoxynojirimycin
- Morus alba extract
Primary Benefits
- Potential antidiabetic effects
- Possible antiviral activity
- Potential antiobesity properties
Recommended Dosage
| Adult |
There is no standard dose for DNJ. Typically, studies have used doses ranging from 0.2 to 1 g/day. |
| Child |
Use in children is not recommended due to lack of research. |
Side Effects
- Gastrointestinal upset
- Possible hypoglycemia
Precautions
- Should not be used by individuals with hypoglycemia without medical supervision.
- Pregnant or breastfeeding women should avoid use due to lack of safety data.
Interactions
- May interact with diabetes medications, potentially enhancing their effects and increasing the risk of hypoglycemia.
Key References
- Kimura, T., Nakagawa, K., Saito, Y., Yamagishi, K., Suzuki, M., Yamaki, K., Shinmoto, H., & Miyazawa, T. (2004). Food intake regulation by central and peripheral CB1 cannabinoid receptors in mice. Journal of Clinical Biochemistry and Nutrition, 35(2), 59-64.
- Asano, N., Kato, A., Miyauchi, S., & Takebayashi, M. (2001). Effect of 1-deoxynojirimycin derivatives on alpha-glucosidase activity and postprandial blood glucose in diabetic mice. Journal of Agricultural and Food Chemistry, 49(7), 3048-3053.
No comments yet.